Abstract
The COVID-19 pandemic has driven the need for accurate data analysis and forecasting to guide public health decisions. In this study, we utilized ARIMA and ARIMAX models to predict short-term trends in confirmed COVID-19 cases across different regions, including the United States, Asia, Europe, Africa, and the Americas. Comparisons were made between ARIMA and auto.arima models, and anomaly detection was performed to investigate discrepancies between predictions and actual data. The study also explored the relationship between vaccination rates and new case numbers, and examined how socioeconomic factors such as GDP per capita, HDI, and healthcare resources influenced COVID-19 incidence rates across countries. Our findings provide insights into the effectiveness of predictive models and the significant impact of socioeconomic factors on the spread of the virus, contributing valuable information for future epidemic prevention and control strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.